- Disease: Respiratory syncytial virus infection
- Study type: Observational Cohort Study, Prevention
- Study type descriptors: Retrospective, Multicentre
- Objective: To assess nirsevimab’s effectiveness in infants born in Catalonia between April and September 2023 during their first epidemic season
- Number of participants enrolled: 26525
- Study enrolling from to
- Study includes follow-up for 4 months
- Standardisation: ICD-10
Study Data
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to